U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. - Wikidata - awgldk - TriplyDB

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.

http://www.wikidata.org/entity/Q33400986

about

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis How could patient reported outcomes improve patient management in chronic myeloid leukemia?The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population.Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers.Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators.Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.Molecular profiling of childhood cancer: Biomarkers and novel therapies Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD)Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome.Genomic and Epigenomic Alterations in Cancer AACR Cancer Progress Report 2015 Redox regulation of Janus kinase: The elephant in the room.Elevated viral restriction factor levels in cortical blood vessels in schizophrenia.JNK inhibitors as anti-inflammatory and neuroprotective agents.Apoptosis deregulation in myeloproliferative neoplasms.Genetic Interactions of STAT3 and Anticancer Drug Development.STAT3 inhibitors: finding a home in lymphoma and leukemia.Optimizing dosing of oncology drugs.Bone morbidity in chronic myeloproliferative neoplasms.Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Measuring quality of life in acute myeloid leukemia: limitations and future directions Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?Neuroprosthetics and the science of patient input.Myelofibrosis: an update on drug therapy in 2016.Management of myelofibrosis: JAK inhibition and beyond.Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.Expanding Role of Data Science and Bioinformatics in Drug Discovery and Development.Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

P2860

Q24186554-0E1FB808-742D-4B03-A5E8-6090777A3EEF Q26996258-03F21F07-DA23-4E11-91F4-AE09540D678F Q30241092-7AC002F4-893D-45E4-B40A-4D38DD102FF4 Q30964688-2AF370E5-6AAD-466F-9F6D-891C89C72DB9 Q33405766-A3600333-0979-4DC3-B26A-5B5799BB8FCD Q33430113-A5FEB405-9A2C-4455-9CB6-7B41880F98C6 Q33436870-31E698E2-4326-4ACB-A1E9-6DD5F2671B6B Q33652833-A147EAFB-D806-4ADD-AC90-931417138CEB Q34294698-F0460666-FEE5-42FD-A87D-A1213E55AFBF Q34361391-F3708E61-E21B-41F1-BE9E-C325C48FB784 Q34434935-FC9E5634-478B-4144-9704-0C644AD20E3F Q35130847-4B1758BE-92DD-46E3-BE0C-E4DF6D0F9C5E Q35244917-5818F5BA-2024-40F3-94EA-A35BB473105A Q36250783-F7972267-F5D0-4AF9-AE80-4E844FFC4A5F Q36698172-7EA59FA8-BDCA-461F-9028-F4706B4A7F9D Q36727581-8E872C8C-9D57-4BC5-A914-3E6A615B08A9 Q37057145-75F5B663-D62D-43A2-BB14-257FA0795FFC Q37210896-49064CD3-2D04-4882-BCD0-1F569AEEC9C1 Q37421820-D21A2BB4-6BC8-4DD5-9C97-DA3F11A2DC4B Q37672679-EB894761-2927-42EB-AA43-A2F619643561 Q38097866-1D41899C-12CE-4BF1-8A4C-5B19D1CE9B97 Q38184437-69BFF05B-7AAE-465C-BA2B-3FF7C079A88B Q38198930-C5D519F5-7CD4-400D-B9B8-E9590070F8F3 Q38202556-30B5B0C9-5CE1-46D6-AF3B-7433E2D81565 Q38238161-1BC4002D-3225-4124-8BC1-20BC340C620C Q38513219-EB0B920B-196E-4FF8-B08E-5FA3B076F34D Q38636718-E9E057DE-7596-4BB2-88FA-15BC11F96F29 Q38751230-E02A2677-7281-4EE0-A1C3-12740274F609 Q38844175-F763A99E-5EC9-466E-A31A-097AFEE5ABAC Q38868066-789D3D8B-2E50-4D77-A08D-DF3D1FA8443F Q38879975-0A6CD002-293C-44DD-B861-73881954C71D Q38908065-B1A9936E-AE75-45FE-9D3E-2020709FFB57 Q38989215-302EEF5E-AE40-407F-8C8F-98AB232E1B0F Q39232415-962A274A-CAFA-4EB4-B9D3-43AFCEAD944D Q39554738-EA03E636-4B0A-4D5E-A178-C28B7AE914D8 Q40692620-50230A59-9C22-4000-BF00-3309EFA3543F Q40996798-2545D667-2AE7-497F-8AB4-B6D9F6E9FAE5 Q41490661-D256B18D-47BA-4614-92B4-4806D57D3160 Q45951517-25B30910-3DC2-4E25-8ADC-38164DE73534 Q45957917-4B13B033-883B-4308-94B2-30B6278863D0

P2860

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.

http://www.wikidata.org/entity/Q33400986

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.

@ast

U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.

@en

type

label

U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.

@ast

U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.

@en

prefLabel

U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.

@ast

U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.

@en

P1433

Q33400986-AE1609ED-263D-40C7-8954-847CDA0B32C9

P1476

Q33400986-8170A8E6-B099-4220-92E9-1F993EB9550F

P2093

Q33400986-099F2D69-8B7E-4257-B8F6-D25E1B8E1543

Q33400986-0D2A1CA1-EFCB-4C73-B82F-26A3D21A44B2

Q33400986-2605DEF4-CBDE-4AB5-961E-55F3CAFD06AB

Q33400986-33EBCB45-6527-4788-A849-4A750E2F21EC

Q33400986-75CEC4B3-4A2B-48E6-B462-5DC8F4C857A7

Q33400986-8349970F-E513-47B2-B91A-7EC2076D4DBD

Q33400986-8AB7E893-0638-4610-90F8-604E7A7C4974

Q33400986-9276838A-B98B-4814-8DC9-1354937A7754

Q33400986-A226F54E-247A-48E9-9737-C12127AC9856

Q33400986-BAD138CE-4835-4830-A377-9CB873EE9E5F

P304

Q33400986-A57958B9-CC96-43E4-8A34-7B195A05AC52

P31

Q33400986-D5B967F7-F49E-4D69-B243-FF4139E05232

P356

Q33400986-3EC27A2A-DBB4-4112-931A-980A8DA5984C

P407

Q33400986-2206FDB9-1812-4A98-A22B-C536ECF3FBD2

P433

Q33400986-6A395CE4-9D6C-4120-9F42-1270D8D40C66

P478

Q33400986-42320906-F955-4DE4-8EC9-FE83035F3C07

P50

Q33400986-F7D97423-DC07-4F32-B355-110DD8A201CD

P577

Q33400986-8FECDB2A-6786-4727-8318-F01FB923F86A

P698

Q33400986-D69AA595-7AC7-498F-8C31-8269CA3109D1

P921

Q33400986-52E6E29B-6209-49E5-967D-170735C1A7E5

Q33400986-7E9604B4-9F63-4765-BF9E-7B514D829362

Q33400986-E331138C-3C86-4EB5-B39C-F27A33304FCD

P356

1078-0432.CCR-12-0653

P1433

Clinical Cancer Research

P1476

U.S. Food and Drug Administrat ...... e and high-risk myelofibrosis.

@en

P2093

Albert Deisseroth

http://www.w3.org/2001/XMLSchema#string

Ann Farrell

http://www.w3.org/2001/XMLSchema#string

Atiqur Rahman

http://www.w3.org/2001/XMLSchema#string

Edvardas Kaminskas

http://www.w3.org/2001/XMLSchema#string

Haleh Saber

http://www.w3.org/2001/XMLSchema#string

Hong L Lu

http://www.w3.org/2001/XMLSchema#string

Jian Wang

http://www.w3.org/2001/XMLSchema#string

Joseph Grillo

http://www.w3.org/2001/XMLSchema#string

Julie Bullock

http://www.w3.org/2001/XMLSchema#string

Laurie B Burke

http://www.w3.org/2001/XMLSchema#string

P304

3212-3217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-0653

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Christine Garnett

P577

2012-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22544377

http://www.w3.org/2001/XMLSchema#string

P921

ruxolitinib phosphate